(NASDAQ: FOLD) Amicus Therapeutics's forecast annual revenue growth rate of 15.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.77%.
Amicus Therapeutics's revenue in 2025 is $598,704,000.On average, 12 Wall Street analysts forecast FOLD's revenue for 2025 to be $197,427,532,030, with the lowest FOLD revenue forecast at $187,313,802,326, and the highest FOLD revenue forecast at $206,365,748,915. On average, 12 Wall Street analysts forecast FOLD's revenue for 2026 to be $239,335,643,855, with the lowest FOLD revenue forecast at $222,721,112,295, and the highest FOLD revenue forecast at $252,917,290,638.
In 2027, FOLD is forecast to generate $284,292,067,134 in revenue, with the lowest revenue forecast at $257,915,534,115 and the highest revenue forecast at $309,767,682,192.